0000315066-18-000119.txt : 20180131 0000315066-18-000119.hdr.sgml : 20180131 20180131163149 ACCESSION NUMBER: 0000315066-18-000119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180129 FILED AS OF DATE: 20180131 DATE AS OF CHANGE: 20180131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 18563150 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Menlo Therapeutics, Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4085 CAMPBELL AVENUE, SUITE 200 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-486-1416 MAIL ADDRESS: STREET 1: 4085 CAMPBELL AVENUE, SUITE 200 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2018-01-29 0 0001566044 Menlo Therapeutics, Inc. MNLO 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 0 1 See Remark 1 Common Stock 2018-01-29 4 C 0 813478 A 813478 I F-Prime Capital Partners Healthcare Fund IV LP Common Stock 2018-01-29 4 C 0 304576 A 1118054 I F-Prime Capital Partners Healthcare Fund IV LP Series B Preferred Stock 2018-01-29 4 C 0 2194357 D Common Stock 813478 0 I F-Prime Capital Partners Healthcare Fund IV LP Series C Preferred Stock 2018-01-29 4 C 0 821596 D Common Stock 304576 0 I F-Prime Capital Partners Healthcare Fund IV LP On January 29, 2018, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into approximately 0.3707 shares of the Issuer's common stock. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund IV LP is F-Prime Capital Partners Healthcare Advisors Fund IV LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the general partner of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2018-01-31